Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture.
null nullRobert V O'TooleDeborah M SteinNathan N O'HaraKatherine P FreyTara J TaylorDaniel O ScharfsteinAnthony R CarliniKuladeep SudiniYasmin DeganiGerard P SlobogeanElliott R HautWilliam ObremskeyReza FiroozabadiMichael J BosseSamuel Z GoldhaberDebra MarvelRenan C CastilloPublished in: The New England journal of medicine (2023)
In patients with extremity fractures that had been treated operatively or with any pelvic or acetabular fracture, thromboprophylaxis with aspirin was noninferior to low-molecular-weight heparin in preventing death and was associated with low incidences of deep-vein thrombosis and pulmonary embolism and low 90-day mortality. (Funded by the Patient-Centered Outcomes Research Institute; PREVENT CLOT ClinicalTrials.gov number, NCT02984384.).
Keyphrases
- pulmonary embolism
- venous thromboembolism
- cardiovascular events
- low dose
- direct oral anticoagulants
- inferior vena cava
- antiplatelet therapy
- growth factor
- hip fracture
- rectal cancer
- coronary artery disease
- type diabetes
- cardiovascular disease
- soft tissue
- risk factors
- total hip arthroplasty
- acute coronary syndrome
- metabolic syndrome
- anti inflammatory drugs